ARS Pharmaceuticals, Inc (SPRY) — Cash Flow Quality Index

Latest as of December 2024: 0.84x

ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow Quality Index of 0.84x as of December 2024. Operating cash flow of $42.00 Million is below net income of $49.93 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore SPRY cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

0.84x
Operating CF / Net Income

Operating Cash Flow

$42.00 Million
USD

Net Income

$49.93 Million
USD

Data as of

Dec 2024
Most recent filing

ARS Pharmaceuticals, Inc Cash Flow Quality Index (2024–2024)

Historical Cash Flow Quality Index for ARS Pharmaceuticals, Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash flow conversion of ARS Pharmaceuticals, Inc.

Annual Cash Flow Quality Index for ARS Pharmaceuticals, Inc (2024–2024)

Year-by-year earnings quality comparison for ARS Pharmaceuticals, Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2024 1.69x $13.55 Million $8.00 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.